[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 highlights for Guardant Health, Inc. (GH): Co-Chief Executive Officer and Director Helmy Eltoukhy reported two routine RSU vesting events and related tax-withholding sales over 30 June-1 July 2025.

• RSU vesting (Code “M”): 4,815 shares vested on 30 Jun 2025 and 23,997 shares vested on 1 Jul 2025, totalling 28,812 shares acquired at $0 exercise price.
• Tax withholding sales (Code “F”): 2,441 shares sold at $52.04 and 12,162 shares sold at $50.71 to cover payroll taxes, for an aggregate 14,603 shares disposed.
• Net change: Insider’s direct common-stock position rose by 14,209 shares, bringing total direct ownership to 2,423,499 shares. He also continues to hold 143,983 unvested RSUs.
• Derivative section clarifies the vesting schedules: a 4-installment 2025 grant and a previously granted award that vests quarterly over 24 months.

All transactions are routine equity-compensation events; no open-market purchases or discretionary sales were reported. The filing signals ongoing insider equity accumulation and substantial alignment, but does not reveal new operational or financial information about Guardant Health.

Positive

• Net insider accumulation: CEO’s direct holdings increased by 14,209 shares, reflecting continued equity alignment with shareholders.
• Significant ownership: Post-transaction stake stands at 2,423,499 shares plus 143,983 RSUs, suggesting long-term commitment.

Negative

• None.

Insights

Financial Analyst

TL;DR Routine RSU vesting; CEO nets 14k shares, maintains 2.4 M stake—neutral fundamental impact, slight positive sentiment.

The Form 4 shows standard compensation mechanics: RSUs from 2025 grants vested and were converted into common shares. Mandatory sell-to-cover transactions removed 14,603 shares at prevailing market prices (~$51 average), leaving a net gain of 14,209 shares. The insider now owns more than 2.4 million shares plus 144 k RSUs, underscoring sizeable exposure to Guardant’s equity performance. Because sales were solely for tax obligations and no discretionary selling occurred, the signal is neutral-to-slightly positive—it indicates commitment but offers no new insight into company fundamentals. From a portfolio perspective, the activity is not material to valuation or near-term catalyst tracking.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eltoukhy Helmy

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		M		4,815	A	$0	2,414,105	D
Common Stock	06/30/2025		F		2,441(1)	D	$52.04	2,411,664	D
Common Stock	07/01/2025		M		23,997	A	$0	2,435,661	D
Common Stock	07/01/2025		F		12,162(1)	D	$50.71	2,423,499	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	06/30/2025		M			4,815	(2)	(3)	Common Stock	4,815	$0	9,629	D
Restricted Stock Units	$0	07/01/2025		M			23,997	(4)	(3)	Common Stock	23,997	$0	143,983	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on March 12, 2025 that vests in four equal installments on the last day of each calendar quarter, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025.

3. Not applicable for Restricted Stock Units.

4. This restricted stock unit award vested with respect to 1/3 of the shares on January 1, 2025. The remaining shares vest quarterly for the remaining twenty-four months.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Helmy Eltoukhy	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Guardant Health (GH) shares did CEO Helmy Eltoukhy acquire?

He acquired 28,812 shares through RSU vesting on 30 Jun and 1 Jul 2025.

Why were some GH shares sold immediately after vesting?

The 14,603 shares were sold under Code “F” to satisfy payroll tax withholding requirements.

What is Helmy Eltoukhy’s total GH ownership after these transactions?

He directly owns 2,423,499 common shares and 143,983 unvested RSUs.

At what prices were the tax-withholding sales executed?

Shares were sold at $52.04 on 30 Jun 2025 and $50.71 on 1 Jul 2025.

Do the transactions indicate any discretionary selling by the CEO?

No. All dispositions were labeled Code “F,” indicating automatic sales strictly for tax purposes.